Research Overview

Jane Newburger's goals are to improve the diagnosis, treatment, and outcome of children with Kawasaki disease and to minimize neurologic problems that may occur after surgery for congenital heart disease. Dr. Newburger has focused on performing randomized trials of new therapies for these conditions.

Dr. Newburger designed an NIH-funded multicenter randomized trial comparing treatments for Kawasaki disease and directed the coordinating center for the study. The first phase of that trial compared high-dose intravenous gamma globulin plus aspirin to aspirin alone during the acute stage of the disease; the second phase compared the effects of two dose regimens of intravenous gamma globulin. Her other prospective studies in Kawasaki disease have focused on its epidemiology and long-term effects.

Recent dramatic reductions in cardiac surgical mortality have been accompanied by the recognition that the survivors frequently are frequently left with neurologic deficits, including mental retardation, seizures, cerebral palsy, and lifelong language and learning disorders. The majority of such brain injuries may be attributable to the support techniques used to protect vital organs during cardiac repair.

One of Dr. Newburger's early studies drew upon the database of the Regional Infant Cardiac Program, a prospective cohort study that collected perioperative and follow-up data on children with heart disease in New England. This work demonstrated that longer duration of cyanosis--reduced oxygen to the tissues--had an adverse effect on cognitive function. Subsequently, she has been principal investigator for a series of randomized clinical trials comparing the effects of different techniques for vital organ support during surgery--first on how well the patient does after surgery and, more recently, on the patient's subsequent neurologic and developmental function.

Research Background

Jane Newburger received her MD from Harvard Medical School and MPH from Harvard School of Public Health. She completed an internship, residency, and fellowship at Boston Children's Hospital.

 

Education

Undergraduate School

Bryn Mawr College
1971 Bryn Mawr PA

Medical School

Harvard Medical School
1974 Boston MA

Internship

Boston Children's Hospital
1975 Boston MA

Residency

Boston Children's Hospital
1976 Boston MA

Fellowship

Boston Children's Hospital
1979 Boston MA

Media

Caregiver Profile

Meet Dr. Jane Newburger

Publications

  1. Six-Month Outcomes in the Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children Study. JAMA Pediatr. 2025 Jan 13. View Abstract
  2. Evaluating the factor structure of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV) in adults with congenital heart disease. Clin Neuropsychol. 2024 Dec 31; 1-12. View Abstract
  3. Noncoding variants and sulcal patterns in congenital heart disease: Machine learning to predict functional impact. iScience. 2025 Feb 21; 28(2):111707. View Abstract
  4. Correction: Demonstrating responsiveness of the pediatric cardiac quality of life inventory in children and adolescents undergoing arrhythmia ablation, heart transplantation, and valve surgery. Qual Life Res. 2024 Dec; 33(12):3469. View Abstract
  5. Features of hyperinflammation link the biology of Epstein-Barr virus infection and cytokine storm syndromes. J Allergy Clin Immunol. 2024 Nov 30. View Abstract
  6. Design and rationale of the COVID vaccine-associated myocarditis/pericarditis (CAMP) study. Am Heart J. 2024 Nov 26; 281:32-42. View Abstract
  7. Genome Sequencing is Critical for Forecasting Outcomes Following Congenital Cardiac Surgery. medRxiv. 2024 Nov 15. View Abstract
  8. Family Socioeconomic Status and Neurodevelopment Among Patients With Dextro-Transposition of the Great Arteries. JAMA Netw Open. 2024 Nov 04; 7(11):e2445863. View Abstract
  9. Development and validation of an open-source pipeline for automatic population of case report forms from electronic health records: a pediatric multi-center prospective study. EBioMedicine. 2024 Oct; 108:105337. View Abstract
  10. The Role of Specialists in Care Integration: A Primary Responsibility. J Pediatr. 2025 Jan; 276:114276. View Abstract
  11. Characterizing Long COVID in Children and Adolescents. JAMA. 2024 08 21. View Abstract
  12. A Thrombolytic Protocol of Bivalirudin for Giant Coronary Artery Aneurysms and Thrombosis in Kawasaki Disease. J Pediatr. 2024 Dec; 275:114233. View Abstract
  13. Severe Features of Systemic Juvenile Idiopathic Arthritis in Patients With Congenital Heart Disease. J Rheumatol. 2024 Aug 01; 51(8):811-817. View Abstract
  14. Demonstrating responsiveness of the pediatric cardiac quality of life inventory in children and adolescents undergoing arrhythmia ablation, heart transplantation, and valve surgery. Qual Life Res. 2024 Sep; 33(9):2465-2475. View Abstract
  15. Identifying novel data-driven subgroups in congenital heart disease using multi-modal measures of brain structure. Neuroimage. 2024 Aug 15; 297:120721. View Abstract
  16. Child Opportunity Index and Pediatric Extracorporeal Membrane Oxygenation Outcomes; the Role of Diagnostic Category. Crit Care Med. 2024 Oct 01; 52(10):1587-1601. View Abstract
  17. Impact of Social Determinants of Health on Predictive Models for Outcomes After Congenital Heart Surgery. J Am Coll Cardiol. 2024 Jun 18; 83(24):2440-2454. View Abstract
  18. Meta-regression of sulcal patterns, clinical and environmental factors on neurodevelopmental outcomes in participants with multiple CHD types. Cereb Cortex. 2024 06 04; 34(6). View Abstract
  19. Repeat Repair After Translocation of an Anomalous Left Coronary Artery. Ann Thorac Surg. 2024 08; 118(2):506-509. View Abstract
  20. Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design. PLoS One. 2024; 19(5):e0285635. View Abstract
  21. Shining a Light: Ocular Coherence Tomography and the Pathology of Late Convalescent Kawasaki Disease. JACC Adv. 2024 Jun; 3(6):100938. View Abstract
  22. De novo variants in FRYL are associated with developmental delay, intellectual disability, and dysmorphic features. Am J Hum Genet. 2024 04 04; 111(4):742-760. View Abstract
  23. Placenta-Heart-Brain Connection in Congenital Heart Disease. J Am Heart Assoc. 2024 Mar 05; 13(5):e033875. View Abstract
  24. Neurodevelopmental Outcomes for Individuals With Congenital Heart Disease: Updates in Neuroprotection, Risk-Stratification, Evaluation, and Management: A Scientific Statement From the American Heart Association. Circulation. 2024 03 26; 149(13):e997-e1022. View Abstract
  25. Preoperative Hemodynamics Impact the Benefit of Fenestration on Fontan Postoperative Length of Stay. JACC Adv. 2024 Mar; 3(3). View Abstract
  26. Stress Ulcer Prophylaxis Versus Placebo-A Blinded Pilot Randomized Controlled Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease. Pediatr Crit Care Med. 2024 Feb 01; 25(2):118-127. View Abstract
  27. Updated Case Definition of MIS-C and Implications for Clinical Care. Pediatrics. 2024 Jan 01; 153(2). View Abstract
  28. Neuroimaging and Neurodevelopmental Outcomes Among Individuals With Complex Congenital Heart Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 12 05; 82(23):2225-2245. View Abstract
  29. Social Drivers of Health and Pediatric Extracorporeal Membrane Oxygenation Outcomes. Pediatrics. 2023 Dec 01; 152(6). View Abstract
  30. Association of genetic and sulcal traits with executive function in congenital heart disease. Ann Clin Transl Neurol. 2024 02; 11(2):278-290. View Abstract
  31. Elevation of IL-17 Cytokines Distinguishes Kawasaki Disease From Other Pediatric Inflammatory Disorders. Arthritis Rheumatol. 2024 02; 76(2):285-292. View Abstract
  32. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Jan; 11(1):e27-e37. View Abstract
  33. Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. J Clin Invest. 2023 11 15; 133(22). View Abstract
  34. School age and adolescent heart failure following the Norwood procedure. J Heart Lung Transplant. 2024 Mar; 43(3):453-460. View Abstract
  35. Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVR III Study. Circulation. 2023 10 24; 148(17):1330-1339. View Abstract
  36. Postoperative Troponin Levels in Children Undergoing Open Heart Surgery With and Without Coronary Intervention. Pediatr Cardiol. 2024 Jan; 45(1):184-195. View Abstract
  37. Genetic and clinical variables act synergistically to impact neurodevelopmental outcomes in children with single ventricle heart disease. Commun Med (Lond). 2023 Sep 27; 3(1):127. View Abstract
  38. Chronic Medication Burden After Cardiac Surgery for Pediatric Medicaid Beneficiaries. J Am Coll Cardiol. 2023 09 26; 82(13):1331-1340. View Abstract
  39. Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium. EClinicalMedicine. 2023 Oct; 64:102212. View Abstract
  40. Design and Harmonization Approach for the Multi-Institutional Neurocognitive Discovery Study (MINDS) of Adult Congenital Heart Disease (ACHD) Neuroimaging Ancillary Study: A Technical Note. J Cardiovasc Dev Dis. 2023 Sep 06; 10(9). View Abstract
  41. Differences in Quality of Life in Children Across the Spectrum of Congenital Heart Disease. J Pediatr. 2023 12; 263:113701. View Abstract
  42. Inpatient Screening for Early Identification of Developmental Risk in Infants with Congenital Heart Defects. J Pediatr. 2023 12; 263:113687. View Abstract
  43. Impact of Residual Lesion Severity on Neurodevelopmental Outcomes Following Congenital Heart Surgery in Infancy and Childhood. Pediatr Cardiol. 2024 Dec; 45(8):1676-1691. View Abstract
  44. Histopathology of resected tissue from repair of anomalous aortic origin of a coronary artery: Potential mechanism of coronary artery compression. JTCVS Open. 2023 Sep; 15:412-423. View Abstract
  45. Trends in surgical management of anomalous aortic origin of the coronary artery over 2 decades. JTCVS Open. 2023 Dec; 16:757-770. View Abstract
  46. Cardiac Magnetic Resonance Imaging to Determine Single Ventricle Function in a Pediatric Population is Feasible in a Large Trial Setting: Experience from the Single Ventricle Reconstruction Trial Longitudinal Follow up. Pediatr Cardiol. 2023 Oct; 44(7):1454-1461. View Abstract
  47. Neurological and Psychological Sequelae Associated With Multisystem Inflammatory Syndrome in Children. JAMA Netw Open. 2023 07 03; 6(7):e2324369. View Abstract
  48. Living with Congenital Aortic Stenosis: Exercise Restriction, Patterns of Adherence, and Quality of Life. Pediatr Cardiol. 2024 Oct; 45(7):1430-1439. View Abstract
  49. Variation in Early Anakinra Use and Short-Term Outcomes in Multisystem Inflammatory Syndrome in Children. Arthritis Rheumatol. 2023 08; 75(8):1466-1476. View Abstract
  50. Preterm congenital heart disease and neurodevelopment: the importance of looking beyond the initial hospitalization. J Perinatol. 2023 07; 43(7):958-962. View Abstract
  51. Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design. medRxiv. 2023 May 12. View Abstract
  52. Contribution of Previously Unrecognized RNA Splice-Altering Variants to Congenital Heart Disease. Circ Genom Precis Med. 2023 06; 16(3):224-231. View Abstract
  53. Failure of Risk Prediction Modeling for IVIG Resistance in Kawasaki Disease. Pediatrics. 2023 05 01; 151(5). View Abstract
  54. Single Ventricle Reconstruction III: Brain Connectome and Neurodevelopmental Outcomes: Design, Recruitment, and Technical Challenges of a Multicenter, Observational Neuroimaging Study. Diagnostics (Basel). 2023 Apr 30; 13(9). View Abstract
  55. Long-Term Health Care Utilization After Cardiac Surgery in Children Covered Under Medicaid. J Am Coll Cardiol. 2023 04 25; 81(16):1605-1617. View Abstract
  56. Single Ventricle Reconstruction III: Brain Connectome and Neurodevelopmental Outcomes: Design, Recruitment, and Technical Challenges of a Multicenter, Observational Neuroimaging Study. medRxiv. 2023 Apr 17. View Abstract
  57. MIS-C across three SARS-CoV-2 variants: Changes in COVID-19 testing and clinical characteristics in a cohort of U.S. children. Eur J Pediatr. 2023 Jun; 182(6):2865-2872. View Abstract
  58. Social cognition and behavioral outcomes in congenital heart disease: profiles and neuropsychiatric comorbidities. Child Neuropsychol. 2023 11; 29(7):1041-1063. View Abstract
  59. SARS-CoV-2 Variants and Multisystem Inflammatory Syndrome in Children. N Engl J Med. 2023 Apr 27; 388(17):1624-1626. View Abstract
  60. Impact of Neighborhood Socioeconomic Status on Outcomes Following First-Stage Palliation of Single Ventricle Heart Disease. J Am Heart Assoc. 2023 03 21; 12(6):e026764. View Abstract
  61. Association of Predicted Damaging De Novo Variants on Ventricular Function in Individuals With Congenital Heart Disease. Circ Genom Precis Med. 2023 04; 16(2):e003900. View Abstract
  62. A New Definition for Multisystem Inflammatory Syndrome in Children. Pediatrics. 2023 03 01; 151(3). View Abstract
  63. Evidence-Based Assessment of Congenital Heart Disease Genes to Enable Returning Results in a Genomic Study. Circ Genom Precis Med. 2023 04; 16(2):e003791. View Abstract
  64. Long-Term Quality of Life in Congenital Heart Disease Surgical Survivors: Multicenter Retrospective Study of Surgical and ICU Explanatory Factors. Pediatr Crit Care Med. 2023 05 01; 24(5):391-398. View Abstract
  65. Computed tomography angiography (CTA) of anomalous aortic origin of a coronary artery (AAOCA): Which measurements are accurate and reliable? J Cardiovasc Comput Tomogr. 2023 Mar-Apr; 17(2):130-137. View Abstract
  66. Reducing Perioperative Brain Injury in Congenital Heart Disease: A Ray of Hope. J Am Coll Cardiol. 2023 01 24; 81(3):267-269. View Abstract
  67. Association of Potentially Damaging De Novo Gene Variants With Neurologic Outcomes in Congenital Heart Disease. JAMA Netw Open. 2023 01 03; 6(1):e2253191. View Abstract
  68. Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in Children. JAMA Netw Open. 2023 01 03; 6(1):e2248987. View Abstract
  69. The Notch1/CD22 signaling axis disrupts Treg function in SARS-CoV-2-associated multisystem inflammatory syndrome in children. J Clin Invest. 2023 01 03; 133(1). View Abstract
  70. Development of the Residual Lesion Score for congenital heart surgery: the RAND Delphi methodology. Cardiol Young. 2023 Jun; 33(6):977-990. View Abstract
  71. Feasibility and Caregiver Receptiveness to Anxiety Screening in Pediatric Cardiology Clinic: A Pilot Study. Clin Pediatr (Phila). 2023 06; 62(6):597-604. View Abstract
  72. SARS-CoV-2-Related Mitigation Measures and Insights Into Kawasaki Disease. JAMA Pediatr. 2022 12 01; 176(12):1167-1168. View Abstract
  73. Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease. J Am Coll Cardiol. 2022 12 13; 80(24):2301-2310. View Abstract
  74. Tachyarrhythmias During Hospitalization for COVID-19 or Multisystem Inflammatory Syndrome in Children and Adolescents. J Am Heart Assoc. 2022 10 18; 11(20):e025915. View Abstract
  75. A machine-learning algorithm for diagnosis of multisystem inflammatory syndrome in children and Kawasaki disease in the USA: a retrospective model development and validation study. Lancet Digit Health. 2022 10; 4(10):e717-e726. View Abstract
  76. Contemporary Socioeconomic and Childhood Opportunity Disparities in Congenital Heart Surgery. Circulation. 2022 10 25; 146(17):1284-1296. View Abstract
  77. Intraoperative Residual Lesion Score Predicts Predischarge Major Residual Lesions and Reinterventions Following Congenital Heart Surgery. J Am Coll Cardiol. 2022 09 20; 80(12):1202-1204. View Abstract
  78. The pediatric heart network's study on long-term outcomes of children with HLHS and the impact of Norwood Shunt type in the single ventricle reconstruction trial cohort (SVRIII): Design and adaptations. Am Heart J. 2022 Dec; 254:216-227. View Abstract
  79. Residual Lesion Severity Predicts Midterm Outcomes After Congenital Aortic Valve Repair. Ann Thorac Surg. 2023 01; 115(1):159-165. View Abstract
  80. SARS-CoV-2-specific T cell responses in patients with multisystem inflammatory syndrome in children. Clin Immunol. 2022 Oct; 243:109106. View Abstract
  81. Sleep Patterns in Young Children with Congenital Heart Disease. J Pediatr. 2023 01; 252:198-203.e2. View Abstract
  82. Long-Term Outcomes of Patients Requiring Unplanned Repeated Interventions After Surgery for Congenital Heart Disease. J Am Coll Cardiol. 2022 06 28; 79(25):2489-2499. View Abstract
  83. Association of Acute Anti-inflammatory Treatment With Medium-term Outcomes for Coronary Artery Aneurysms in Kawasaki Disease. CJC Pediatr Congenit Heart Dis. 2022 Aug; 1(4):174-183. View Abstract
  84. Epidemiological and Clinical Features of Kawasaki Disease During the COVID-19 Pandemic in the United States. JAMA Netw Open. 2022 06 01; 5(6):e2217436. View Abstract
  85. Intraoperative Technical Performance Score Predicts Outcomes After Congenital Cardiac Surgery. Ann Thorac Surg. 2023 02; 115(2):471-477. View Abstract
  86. Follow-up cardiac magnetic resonance in children with vaccine-associated myocarditis. Eur J Pediatr. 2022 Jul; 181(7):2879-2883. View Abstract
  87. Notch1-CD22-Dependent Immune Dysregulation in the SARS-CoV2-Associated Multisystem Inflammatory Syndrome in Children. Res Sq. 2022 Apr 11. View Abstract
  88. Neither cardiac mitochondrial DNA variation nor copy number contribute to congenital heart disease risk. Am J Hum Genet. 2022 05 05; 109(5):961-966. View Abstract
  89. Comparison of Intraoperative and Discharge Residual Lesion Severity in Congenital Heart Surgery. Ann Thorac Surg. 2022 11; 114(5):1731-1737. View Abstract
  90. Machine Learning to Predict Executive Function in Adolescents with Repaired d-Transposition of the Great Arteries, Tetralogy of Fallot, and Fontan Palliation. J Pediatr. 2022 07; 246:145-153. View Abstract
  91. Neurodevelopmental and Mental Health Outcomes in Patients With Fontan Circulation: A State-of-the-Art Review. Front Pediatr. 2022; 10:826349. View Abstract
  92. Fetal Brain Volume Predicts Neurodevelopment in Congenital Heart Disease. Circulation. 2022 04 12; 145(15):1108-1119. View Abstract
  93. Multicenter Validation of a Machine Learning Algorithm for Diagnosing Pediatric Patients with Multisystem Inflammatory Syndrome and Kawasaki Disease. medRxiv. 2022 Feb 08. View Abstract
  94. Risk Stratification for Congenital Heart Surgery for ICD-10 Administrative Data (RACHS-2). J Am Coll Cardiol. 2022 02 08; 79(5):465-478. View Abstract
  95. Genome-Wide De Novo Variants in Congenital Heart Disease Are Not Associated With Maternal Diabetes or Obesity. Circ Genom Precis Med. 2022 04; 15(2):e003500. View Abstract
  96. Relation of Norwood Shunt Type and Frequency of Arrhythmias at 6 Years (from the Single Ventricle Reconstruction Trial). Am J Cardiol. 2022 04 15; 169:107-112. View Abstract
  97. An integrated framework for identifying clinical-laboratory indicators for novel pandemics: COVID-19 and MIS-C. NPJ Digit Med. 2022 Jan 20; 5(1):9. View Abstract
  98. Multisystem Inflammatory-like Syndrome in a Child Following COVID-19 mRNA Vaccination. Vaccines (Basel). 2021 Dec 30; 10(1). View Abstract
  99. Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial. J Pediatr. 2022 04; 243:173-180.e8. View Abstract
  100. Neurological features in infants with congenital heart disease. Dev Med Child Neurol. 2022 06; 64(6):762-770. View Abstract
  101. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination. Circulation. 2022 02; 145(5):345-356. View Abstract
  102. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. JAMA Cardiol. 2021 12 01; 6(12):1446-1450. View Abstract
  103. Temporal clustering of Kawasaki disease cases around the world. Sci Rep. 2021 11 19; 11(1):22584. View Abstract
  104. Improving Longitudinal Outcomes, Efficiency, and Equity in the Care of Patients With Congenital Heart Disease. J Am Coll Cardiol. 2021 10 26; 78(17):1703-1713. View Abstract
  105. Coagulation profiles and viscoelastic testing in multisystem inflammatory syndrome in children. Pediatr Blood Cancer. 2021 12; 68(12):e29355. View Abstract
  106. Comparison of coronary artery measurements between echocardiograms and cardiac CT in Kawasaki disease patients with aneurysms. J Cardiovasc Comput Tomogr. 2022 Jan-Feb; 16(1):43-50. View Abstract
  107. Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents. EClinicalMedicine. 2021 Oct; 40:101112. View Abstract
  108. Mycobacterium chimaera Outbreak Management and Outcomes at a Large Pediatric Cardiac Surgery Center. Ann Thorac Surg. 2022 08; 114(2):552-559. View Abstract
  109. Abnormal Right-Hemispheric Sulcal Patterns Correlate with Executive Function in Adolescents with Tetralogy of Fallot. Cereb Cortex. 2021 08 26; 31(10):4670-4680. View Abstract
  110. The NHLBI Study on Long-terM OUtcomes after the Multisystem Inflammatory Syndrome In Children (MUSIC): Design and Objectives. Am Heart J. 2022 01; 243:43-53. View Abstract
  111. Coronary artery aneurysms in children is not always Kawasaki disease: a case report on Takayasu arteritis. BMC Rheumatol. 2021 Aug 12; 5(1):27. View Abstract
  112. Therapy for Multisystem Inflammatory Syndrome in Children. Reply. N Engl J Med. 2021 09 23; 385(13):e42. View Abstract
  113. ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism. Cardiol Young. 2021 Aug; 31(8):1213-1219. View Abstract
  114. Differentiating multisystem inflammatory syndrome in children: a single-centre retrospective cohort study. Arch Dis Child. 2022 03; 107(3):e3. View Abstract
  115. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. N Engl J Med. 2021 07 01; 385(1):23-34. View Abstract
  116. Association of Financial Hardship Because of Medical Bills With Adverse Outcomes Among Families of Children With Congenital Heart Disease. JAMA Cardiol. 2021 06 01; 6(6):713-717. View Abstract
  117. Impact of Major Residual Lesions on Outcomes After Surgery for Congenital Heart Disease. J Am Coll Cardiol. 2021 05 18; 77(19):2382-2394. View Abstract
  118. Mistaken MIS-C: A Case Series of Bacterial Enteritis Mimicking MIS-C. Pediatr Infect Dis J. 2021 04 01; 40(4):e159-e161. View Abstract
  119. Association of Damaging Variants in Genes With Increased Cancer Risk Among Patients With Congenital Heart Disease. JAMA Cardiol. 2021 04 01; 6(4):457-462. View Abstract
  120. Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms. Pediatr Rheumatol Online J. 2021 Mar 17; 19(1):31. View Abstract
  121. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021 03 16; 325(11):1074-1087. View Abstract
  122. Biological Pathways in Adolescent Aortic Stiffness. J Am Heart Assoc. 2021 03 16; 10(6):e018419. View Abstract
  123. Detailed Assessment of Left Ventricular Function in Multisystem Inflammatory Syndrome in Children, Using Strain Analysis. CJC Open. 2021 Jul; 3(7):880-887. View Abstract
  124. Socioeconomic and Racial and/or Ethnic Disparities in Multisystem Inflammatory Syndrome. Pediatrics. 2021 05; 147(5). View Abstract
  125. The Electrocardiogram in Multisystem Inflammatory Syndrome in Children: Mind Your Ps and Qs. J Pediatr. 2021 07; 234:10-11. View Abstract
  126. Surgical Repair of Congenital Atresia of the Left Coronary Ostium. JACC Case Rep. 2021 Feb; 3(2):198-201. View Abstract
  127. Myocardial fibrosis in patients with a history of Kawasaki disease. Int J Cardiol Heart Vasc. 2021 Feb; 32:100713. View Abstract
  128. Performance on the ROCF at 8 Years Predicts Academic Achievement at 16 Years in Individuals with Dextro-Transposition of the Great Arteries. J Int Neuropsychol Soc. 2021 10; 27(9):857-864. View Abstract
  129. Six-Year Neurodevelopmental Outcomes for Children With Single-Ventricle Physiology. Pediatrics. 2021 02; 147(2). View Abstract
  130. Comparison Between Currently Recommended Long-Term Medical Management of Coronary Artery Aneurysms After Kawasaki Disease and Actual Reported Management in the Last Two Decades. Pediatr Cardiol. 2021 Mar; 42(3):676-684. View Abstract
  131. Multiple Emergency Department Visits for a Diagnosis of Kawasaki Disease: An Examination of Risk Factors and Outcomes. J Pediatr. 2021 05; 232:127-132.e3. View Abstract
  132. Commentary on Gastrointestinal Symptoms Followed by Shock in a Febrile 7-Year-Old Child during the COVID-19 Pandemic. Clin Chem. 2021 01 08; 67(1):59-60. View Abstract
  133. Challenges to Randomized Trials in Adult and Congenital Cardiac and Thoracic Surgery. Ann Thorac Surg. 2022 05; 113(5):1409-1418. View Abstract
  134. The origins and development of the Cardiac Neurodevelopmental Outcome Collaborative: creating innovative clinical, quality improvement, and research opportunities - Corrigendum. Cardiol Young. 2021 01; 31(1):175. View Abstract
  135. Variation in the management of Kawasaki disease in Australia and New Zealand: A survey of paediatricians. J Paediatr Child Health. 2021 May; 57(5):646-652. View Abstract
  136. Rare genetic variation at transcription factor binding sites modulates local DNA methylation profiles. PLoS Genet. 2020 11; 16(11):e1009189. View Abstract
  137. Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children. Circulation. 2021 01 05; 143(1):78-88. View Abstract
  138. High-Throughput Screening of Kawasaki Disease Sera for Antiviral Antibodies. J Infect Dis. 2020 11 09; 222(11):1853-1857. View Abstract
  139. Regional Brain Growth Trajectories in Fetuses with Congenital Heart Disease. Ann Neurol. 2021 01; 89(1):143-157. View Abstract
  140. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View Abstract
  141. The origins and development of the cardiac neurodevelopment outcome collaborative: creating innovative clinical, quality improvement, and research opportunities. Cardiol Young. 2020 Nov; 30(11):1597-1602. View Abstract
  142. Cardiac Dysfunction in Multisystem Inflammatory Syndrome in Children: A Call to Action. J Am Coll Cardiol. 2020 10 27; 76(17):1962-1964. View Abstract
  143. Variations in practice in cardiac neurodevelopmental follow-up programs. Cardiol Young. 2020 Nov; 30(11):1603-1608. View Abstract
  144. Trajectories in Neurodevelopmental, Health-Related Quality of Life, and Functional Status Outcomes by Socioeconomic Status and Maternal Education in Children with Single Ventricle Heart Disease. J Pediatr. 2021 02; 229:289-293.e3. View Abstract
  145. Socioeconomic Status and Long-term Outcomes in Single Ventricle Heart Disease. Pediatrics. 2020 10; 146(4). View Abstract
  146. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. Arch Dis Child. 2021 03; 106(3):247-252. View Abstract
  147. In Memoriam: Jaqueline A. Noonan. J Am Coll Cardiol. 2020 Sep 22; 76(12):1498-1500. View Abstract
  148. Atrioventricular Block in Children With Multisystem Inflammatory Syndrome. Pediatrics. 2020 11; 146(5). View Abstract
  149. Randomized Controlled Trial of Working Memory Intervention in Congenital Heart Disease. J Pediatr. 2020 12; 227:191-198.e3. View Abstract
  150. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr. 2021 Feb; 180(2):307-322. View Abstract
  151. Screening for Intracranial Aneurysms in Coarctation of the Aorta: A Decision and Cost-Effectiveness Analysis. Circ Cardiovasc Qual Outcomes. 2020 08; 13(8):e006406. View Abstract
  152. Medium-Term Complications Associated With Coronary Artery Aneurysms After Kawasaki Disease: A Study From the International Kawasaki Disease Registry. J Am Heart Assoc. 2020 08 04; 9(15):e016440. View Abstract
  153. Association of Isolated Congenital Heart Disease with Fetal Brain Maturation. AJNR Am J Neuroradiol. 2020 08; 41(8):1525-1531. View Abstract
  154. Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children With Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial. Can J Cardiol. 2020 10; 36(10):1598-1607. View Abstract
  155. Reply. J Pediatr. 2020 09; 224:184-185.e1. View Abstract
  156. De Novo Damaging Variants, Clinical Phenotypes, and Post-Operative Outcomes in Congenital Heart Disease. Circ Genom Precis Med. 2020 08; 13(4):e002836. View Abstract
  157. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020 07 23; 383(4):334-346. View Abstract
  158. Stress ulcer prophylaxis versus placebo-a blinded randomized control trial to evaluate the safety of two strategies in critically ill infants with congenital heart disease (SUPPRESS-CHD). Trials. 2020 Jun 29; 21(1):590. View Abstract
  159. Genomic analyses implicate noncoding de novo variants in congenital heart disease. Nat Genet. 2020 08; 52(8):769-777. View Abstract
  160. Technical Performance Score's Association With Arterial Switch Operation Outcomes. Ann Thorac Surg. 2021 04; 111(4):1367-1373. View Abstract
  161. Multisystem Inflammatory Syndrome in Children in Association With COVID-19. Circulation. 2020 08 04; 142(5):437-440. View Abstract
  162. Registry-based trials: a potential model for cost savings? Cardiol Young. 2020 Jun; 30(6):807-817. View Abstract
  163. Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. J Pediatr. 2020 Jul; 222:261-262. View Abstract
  164. EM-mosaic detects mosaic point mutations that contribute to congenital heart disease. Genome Med. 2020 04 29; 12(1):42. View Abstract
  165. Prevalence and Prognostic Association of a Clinical Diagnosis of Depression in Adult Congenital Heart Disease: Results of the Boston Adult Congenital Heart Disease Biobank. J Am Heart Assoc. 2020 05 05; 9(9):e014820. View Abstract
  166. Management of Myocardial Infarction in Children with Giant Coronary Artery Aneurysms after Kawasaki Disease. J Pediatr. 2020 06; 221:230-234. View Abstract
  167. Systems Analysis Implicates WAVE2 Complex in the Pathogenesis of Developmental Left-Sided Obstructive Heart Defects. JACC Basic Transl Sci. 2020 Apr; 5(4):376-386. View Abstract
  168. Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome: A Decision Analysis. Circ Cardiovasc Qual Outcomes. 2020 04; 13(4):e006127. View Abstract
  169. Abnormal Left-Hemispheric Sulcal Patterns Correlate with Neurodevelopmental Outcomes in Subjects with Single Ventricular Congenital Heart Disease. Cereb Cortex. 2020 03 21; 30(2):476-487. View Abstract
  170. Health-Related Quality of Life in Children, Adolescents, and Adults With a Fontan Circulation: A Meta-Analysis. J Am Heart Assoc. 2020 03 17; 9(6):e014172. View Abstract
  171. Multicentre validation of a computer-based tool for differentiation of acute Kawasaki disease from clinically similar febrile illnesses. Arch Dis Child. 2020 08; 105(8):772-777. View Abstract
  172. Development and Utility of Quality Metrics for Ambulatory Pediatric Cardiology in Kawasaki Disease. Clin Pediatr (Phila). 2020 03; 59(3):245-251. View Abstract
  173. The Bayley-III scale may underestimate neurodevelopmental disability after cardiac surgery in infants. Eur J Cardiothorac Surg. 2020 01 01; 57(1):63-71. View Abstract
  174. Variation in care for children undergoing the Fontan operation for hypoplastic left heart syndrome. Cardiol Young. 2019 Dec; 29(12):1510-1516. View Abstract
  175. The Pediatric Heart Network Residual Lesion Score Study: Design and objectives. J Thorac Cardiovasc Surg. 2020 07; 160(1):218-223.e1. View Abstract
  176. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020 02; 79(2):225-231. View Abstract
  177. Anti-thrombosis management of patients with Kawasaki disease: Results from an international survey. Int J Cardiol. 2020 05 15; 307:154-158. View Abstract
  178. Introduction to the Mini-Symposium: Ethical Dilemmas in Caring for the Hearts of Children. Ann Thorac Surg. 2019 11; 108(5):1277. View Abstract
  179. Behavior and Quality of Life at 6 Years for Children With Hypoplastic Left Heart Syndrome. Pediatrics. 2019 11; 144(5). View Abstract
  180. De novo and recessive forms of congenital heart disease have distinct genetic and phenotypic landscapes. Nat Commun. 2019 10 17; 10(1):4722. View Abstract
  181. Autism and Congenital Heart Disease: Evidence and Unresolved Questions. Pediatrics. 2019 11; 144(5). View Abstract
  182. Abnormalities in cerebral hemodynamics and changes with surgical intervention in neonates with congenital heart disease. J Thorac Cardiovasc Surg. 2020 05; 159(5):2012-2021. View Abstract
  183. Mental health care for parents of babies with congenital heart disease during intensive care unit admission: Systematic review and statement of best practice. Early Hum Dev. 2019 12; 139:104837. View Abstract
  184. A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study. Am Heart J. 2019 11; 217:52-63. View Abstract
  185. Enhancing efficiency and scientific impact of a clinical trials network: the Pediatric Heart Network Integrated CARdiac Data and Outcomes (iCARD) Collaborative. Cardiol Young. 2019 Sep; 29(9):1121-1126. View Abstract
  186. Early-Emerging Sulcal Patterns Are Atypical in Fetuses with Congenital Heart Disease. Cereb Cortex. 2019 07 22; 29(8):3605-3616. View Abstract
  187. Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association. Circulation. 2019 Aug 06; 140(6):e234-e284. View Abstract
  188. Is Echocardiography Critical in Patients With Kawasaki Disease With a Z-Score < 2 6 Weeks From Onset?-Reply. JAMA Pediatr. 2019 07 01; 173(7):700-701. View Abstract
  189. Impact of Socioeconomic Status on Outcomes of Patients with Kawasaki Disease. J Pediatr. 2019 09; 212:87-92. View Abstract
  190. Variation in the management of Kawasaki disease. Arch Dis Child. 2020 10; 105(10):1004-1006. View Abstract
  191. Correction of d-Transposition of the Great Arteries Sooner Rather Than Later. Circulation. 2019 06 11; 139(24):2739-2741. View Abstract
  192. Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population. J Am Heart Assoc. 2019 06 04; 8(11):e011319. View Abstract
  193. Factors Associated With Adverse Outcomes After Repair of Anomalous Coronary From Pulmonary Artery. Ann Thorac Surg. 2019 09; 108(3):785-791. View Abstract
  194. Failure to validate association of mannose-binding lectin deficiency with adverse neurodevelopmental outcomes after cardiac surgery in infants. J Thorac Cardiovasc Surg. 2019 Jun; 157(6):e397-e398. View Abstract
  195. Early Neurodevelopmental Outcomes in Children Supported with ECMO for Cardiac Indications. Pediatr Cardiol. 2019 Jun; 40(5):1072-1083. View Abstract
  196. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. Pediatrics. 2019 06; 143(6). View Abstract
  197. Etanercept as Adjunctive Primary Therapy in Kawasaki Disease. Pediatrics. 2019 06; 143(6). View Abstract
  198. Gestational Age, Birth Weight, and Outcomes Six Years After the Norwood Procedure. Pediatrics. 2019 05; 143(5). View Abstract
  199. PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design. Thromb Haemost. 2019 May; 119(5):844-853. View Abstract
  200. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemp Clin Trials. 2019 04; 79:98-103. View Abstract
  201. The Congenital Heart Technical Skill Study: Rationale and Design. World J Pediatr Congenit Heart Surg. 2019 03; 10(2):137-144. View Abstract
  202. Reflections on mentoring. Congenit Heart Dis. 2019 Mar; 14(2):126-127. View Abstract
  203. Improving neurodevelopmental outcomes in children with congenital heart disease: protocol for a randomised controlled trial of working memory training. BMJ Open. 2019 02 19; 9(2):e023304. View Abstract
  204. Aortic Valve Replacement With Bovine Pericardial Tissue Valve in Children and Young Adults. Circulation. 2019 02 12; 139(7):983-985. View Abstract
  205. Impact of Initial Shunt Type on Echocardiographic Indices in Children After Single Right Ventricle Palliations. Circ Cardiovasc Imaging. 2019 02; 12(2):e007865. View Abstract
  206. Visual-spatial processing style is associated with psychopathology in adolescents with critical congenital heart disease. Clin Neuropsychol. 2019 05; 33(4):760-778. View Abstract
  207. Ascending Aorta Size at Birth Predicts White Matter Microstructure in Adolescents Who Underwent Fontan Palliation. J Am Heart Assoc. 2018 12 18; 7(24):e010395. View Abstract
  208. Association of Initially Normal Coronary Arteries With Normal Findings on Follow-up Echocardiography in Patients With Kawasaki Disease. JAMA Pediatr. 2018 12 01; 172(12):e183310. View Abstract
  209. The Use of Non-ionic Contrast Agent for Lymphangiography and Embolization of the Thoracic Duct. Cardiovasc Intervent Radiol. 2019 Mar; 42(3):481-483. View Abstract
  210. Neurodevelopmental assessment of infants with congenital heart disease in the early postoperative period. Congenit Heart Dis. 2019 Mar; 14(2):236-245. View Abstract
  211. Longitudinal Associations between Neurodevelopment and Psychosocial Health Status in Patients with Repaired D-Transposition of the Great Arteries. J Pediatr. 2019 01; 204:38-45.e1. View Abstract
  212. Variation in care for infants undergoing the Stage II palliation for hypoplastic left heart syndrome. Cardiol Young. 2018 Oct; 28(10):1109-1115. View Abstract
  213. Working Memory Training: A Promising Intervention? Crit Care Med. 2018 07; 46(7):1199-1201. View Abstract
  214. Altered White Matter Microstructure Correlates with IQ and Processing Speed in Children and Adolescents Post-Fontan. J Pediatr. 2018 09; 200:140-149.e4. View Abstract
  215. The Pediatric Heart Network Scholar Award programme: a unique mentored award embedded within a multicentre network. Cardiol Young. 2018 Jun; 28(6):854-861. View Abstract
  216. Renin-Angiotensin-Aldosterone System Inhibitors for Right Ventricular Dysfunction in Tetralogy of Fallot: Quo Vadis? Circulation. 2018 04 03; 137(14):1472-1474. View Abstract
  217. Disparities in Outcomes and Resource Use After Hospitalization for Cardiac Surgery by Neighborhood Income. Pediatrics. 2018 03; 141(3). View Abstract
  218. Heart failure after the Norwood procedure: An analysis of the Single Ventricle Reconstruction Trial. J Heart Lung Transplant. 2018 07; 37(7):879-885. View Abstract
  219. Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. J Am Heart Assoc. 2018 02 10; 7(4). View Abstract
  220. Neighborhood Socioeconomic Status and Outcomes Following the Norwood Procedure: An Analysis of the Pediatric Heart Network Single Ventricle Reconstruction Trial Public Data Set. J Am Heart Assoc. 2018 02 02; 7(3). View Abstract
  221. Transplant-Free Survival and Interventions at 6 Years in the SVR Trial. Circulation. 2018 05 22; 137(21):2246-2253. View Abstract
  222. Kawasaki Disease. Pediatr Rev. 2018 Feb; 39(2):78-90. View Abstract
  223. Graph theory analysis of cortical thickness networks in adolescents with d-transposition of the great arteries. Brain Behav. 2018 02; 8(2):e00834. View Abstract
  224. Coronary Stenosis after Kawasaki Disease: Size Matters. J Pediatr. 2018 03; 194:8-10. View Abstract
  225. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018 Jan; 21(1):64-69. View Abstract
  226. Probabilistic tractography-based thalamic parcellation in healthy newborns and newborns with congenital heart disease. J Magn Reson Imaging. 2018 06; 47(6):1626-1637. View Abstract
  227. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017 Nov; 49(11):1593-1601. View Abstract
  228. Genetic contribution to neurodevelopmental outcomes in congenital heart disease: are some patients predetermined to have developmental delay? Curr Opin Pediatr. 2017 10; 29(5):529-533. View Abstract
  229. Adrenergic receptor genotypes influence postoperative outcomes in infants in the Single-Ventricle Reconstruction Trial. J Thorac Cardiovasc Surg. 2017 11; 154(5):1703-1710.e3. View Abstract
  230. Learning and Memory in Adolescents With Critical Biventricular Congenital Heart Disease. J Int Neuropsychol Soc. 2017 09; 23(8):627-639. View Abstract
  231. Kawasaki disease: Medical therapies. Congenit Heart Dis. 2017 Sep; 12(5):641-643. View Abstract
  232. Kawasaki disease: State of the art. Congenit Heart Dis. 2017 Sep; 12(5):633-635. View Abstract
  233. Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline z Scores. J Am Heart Assoc. 2017 May 31; 6(6). View Abstract
  234. Safety and Efficacy of Warfarin Therapy in Kawasaki Disease. J Pediatr. 2017 10; 189:61-65. View Abstract
  235. Psychiatric Disorders and Function in Adolescents with Tetralogy of Fallot. J Pediatr. 2017 08; 187:165-173. View Abstract
  236. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017 Apr 25; 135(17):e927-e999. View Abstract
  237. Non-invasive Assessment of Cerebral Blood Flow and Oxygen Metabolism in Neonates during Hypothermic Cardiopulmonary Bypass: Feasibility and Clinical Implications. Sci Rep. 2017 03 09; 7:44117. View Abstract
  238. Kawasaki disease and immunisation: A systematic review. Vaccine. 2017 03 27; 35(14):1770-1779. View Abstract
  239. Neurodevelopmental Outcome in Children after Fetal Cardiac Intervention for Aortic Stenosis with Evolving Hypoplastic Left Heart Syndrome. J Pediatr. 2017 05; 184:130-136.e4. View Abstract
  240. Visuospatial processing in adolescents with critical congenital heart disease: Organization, integration, and implications for academic achievement. Child Neuropsychol. 2018 05; 24(4):451-468. View Abstract
  241. Development of Quality Metrics in Ambulatory Pediatric Cardiology. J Am Coll Cardiol. 2017 Feb 07; 69(5):541-555. View Abstract
  242. Reduced cortical volume and thickness and their relationship to medical and operative features in post-Fontan children and adolescents. Pediatr Res. 2017 Jun; 81(6):881-890. View Abstract
  243. Psychiatric Disorders in Adolescents With Single Ventricle Congenital Heart Disease. Pediatrics. 2017 Mar; 139(3). View Abstract
  244. Training fellows in paediatric cardiology: the Harvard experience. Cardiol Young. 2016 Dec; 26(8):1499-1506. View Abstract
  245. A Pediatric Cardiology Fellowship Boot Camp improves trainee confidence. Cardiol Young. 2016 Dec; 26(8):1514-1521. View Abstract
  246. Kawasaki disease and immunisation: Standardised case definition & guidelines for data collection, analysis. Vaccine. 2016 12 12; 34(51):6582-6596. View Abstract
  247. Assessment of Growth 6 Years after the Norwood Procedure. J Pediatr. 2017 01; 180:270-274.e6. View Abstract
  248. White Matter Volume Predicts Language Development in Congenital Heart Disease. J Pediatr. 2017 02; 181:42-48.e2. View Abstract
  249. Implementation of a Quality Improvement Bundle Improves Echocardiographic Imaging after Congenital Heart Surgery in Children. J Am Soc Echocardiogr. 2016 12; 29(12):1163-1170.e3. View Abstract
  250. Completeness and Accuracy of Local Clinical Registry Data for Children Undergoing Heart Surgery. Ann Thorac Surg. 2017 Feb; 103(2):629-636. View Abstract
  251. Early-Term Birth in Single-Ventricle Congenital Heart Disease After the Fontan Procedure: Neurodevelopmental and Psychiatric Outcomes. J Pediatr. 2016 12; 179:96-103. View Abstract
  252. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population. J Am Heart Assoc. 2016 09 15; 5(9). View Abstract
  253. Anomalous Aortic Origin of Coronary Arteries: A Single-Center Experience. Semin Thorac Cardiovasc Surg. 2016 Winter; 28(4):791-800. View Abstract
  254. Kawasaki Disease and Exposure to Fine Particulate Air Pollution. J Pediatr. 2016 10; 177:179-183.e1. View Abstract
  255. Impact of Surgical Complexity on Health-Related Quality of Life in Congenital Heart Disease Surgical Survivors. J Am Heart Assoc. 2016 07 22; 5(7). View Abstract
  256. Trends in Congenital Heart Disease: The Next Decade. Circulation. 2016 Jun 21; 133(25):2716-33. View Abstract
  257. Organizational topology of brain and its relationship to ADHD in adolescents with d-transposition of the great arteries. Brain Behav. 2016 08; 6(8):e00504. View Abstract
  258. Brain in Congenital Heart Disease Across the Lifespan: The Cumulative Burden of Injury. Circulation. 2016 May 17; 133(20):1951-62. View Abstract
  259. Emerging Research Directions in Adult Congenital Heart Disease: A Report From an NHLBI/ACHA Working Group. J Am Coll Cardiol. 2016 Apr 26; 67(16):1956-64. View Abstract
  260. Processing speed, executive function, and academic achievement in children with dextro-transposition of the great arteries: Testing a longitudinal developmental cascade model. Neuropsychology. 2016 10; 30(7):874-885. View Abstract
  261. Kawasaki Disease. J Am Coll Cardiol. 2016 Apr 12; 67(14):1738-49. View Abstract
  262. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp Clin Trials. 2016 05; 48:70-5. View Abstract
  263. Heart block following stage 1 palliation of hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2016 Jul; 152(1):189-94. View Abstract
  264. Neuropsychological Status and Structural Brain Imaging in Adolescents With Single Ventricle Who Underwent the Fontan Procedure. J Am Heart Assoc. 2015 Dec 14; 4(12). View Abstract
  265. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science. 2015 Dec 04; 350(6265):1262-6. View Abstract
  266. Perioperative cerebral hemodynamics and oxygen metabolism in neonates with single-ventricle physiology. Biomed Opt Express. 2015 Dec 01; 6(12):4749-67. View Abstract
  267. Altered Gray Matter in Adolescents with d-Transposition of the Great Arteries. J Pediatr. 2016 Feb; 169:36-43.e1. View Abstract
  268. Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015. J Am Heart Assoc. 2015 Nov 05; 4(11). View Abstract
  269. Growth Asymmetry, Head Circumference, and Neurodevelopmental Outcomes in Infants with Single Ventricles. J Pediatr. 2016 Jan; 168:220-225.e1. View Abstract
  270. Factors affecting Fontan length of stay: Results from the Single Ventricle Reconstruction trial. J Thorac Cardiovasc Surg. 2016 Mar; 151(3):669-675.e1. View Abstract
  271. Coronary Artery Aneurysm Measurement and Z Score Variability in Kawasaki Disease. J Am Soc Echocardiogr. 2016 Feb; 29(2):150-7. View Abstract
  272. Impact of Variability in Echocardiographic Interpretation on Assessment of Adequacy of Repair Following Congenital Heart Surgery: A Pilot Study. Pediatr Cardiol. 2016 Jan; 37(1):144-50. View Abstract
  273. Differentiating standardized clinical assessment and management plans from clinical practice guidelines. Acad Med. 2015 Aug; 90(8):1002. View Abstract
  274. Associations Between Day of Admission and Day of Surgery on Outcome and Resource Utilization in Infants With Hypoplastic Left Heart Syndrome Who Underwent Stage I Palliation (from the Single Ventricle Reconstruction Trial). Am J Cardiol. 2015 Oct 15; 116(8):1263-9. View Abstract
  275. Left Ventricular Strain and Myocardial Fibrosis in Congenital Aortic Stenosis. Am J Cardiol. 2015 Oct 15; 116(8):1257-62. View Abstract
  276. Prevalence of Undiagnosed Structural Heart Disease in Children Undergoing Echocardiography for Kawasaki Disease. Clin Pediatr (Phila). 2016 Jun; 55(6):557-9. View Abstract
  277. Patterns of Lipid Lowering Therapy among Children Ages 8-20 Years. J Pediatr. 2015 Jul; 167(1):113-9.e1. View Abstract
  278. Neurodevelopmental outcomes after cardiac surgery in infancy. Pediatrics. 2015 May; 135(5):816-25. View Abstract
  279. Task Force 8: Pediatric Cardiology Fellowship Training in Research and Scholarly Activity. J Am Coll Cardiol. 2015 Aug 11; 66(6):740-7. View Abstract
  280. Task Force 8: Pediatric Cardiology Fellowship Training in Research and Scholarly Activity. SPCTPD/ACC/AAP/AHA. Circulation. 2015 Aug 11; 132(6):e107-13. View Abstract
  281. 2015 SPCTPD/ACC/AAP/AHA Training Guidelines for Pediatric Cardiology Fellowship Programs (Revision of the 2005 Training Guidelines for Pediatric Cardiology Fellowship Programs). J Am Coll Cardiol. 2015 Mar 13. View Abstract
  282. Relationship of white matter network topology and cognitive outcome in adolescents with d-transposition of the great arteries. Neuroimage Clin. 2015; 7:438-48. View Abstract
  283. Quality of life in pediatric patients affected by electrophysiologic disease. Heart Rhythm. 2015 May; 12(5):899-908. View Abstract
  284. Management of Kawasaki disease in resource-limited settings. Pediatr Infect Dis J. 2015 Jan; 34(1):94-6. View Abstract
  285. Executive Function in Children and Adolescents with Critical Cyanotic Congenital Heart Disease. J Int Neuropsychol Soc. 2015 Jan; 21(1):34-49. View Abstract
  286. Carotid artery intima-media thickness measurements in the youth: reproducibility and technical considerations. J Am Soc Echocardiogr. 2015 Mar; 28(3):309-16. View Abstract
  287. Idiopathic pericarditis and pericardial effusion in children: contemporary epidemiology and management. J Am Heart Assoc. 2014 Nov 07; 3(6):e001483. View Abstract
  288. Impact of initial shunt type on cardiac size and function in children with single right ventricle anomalies before the Fontan procedure: the single ventricle reconstruction extension trial. J Am Coll Cardiol. 2014 Nov 11; 64(19):2026-35. View Abstract
  289. Predictors of health-related quality of life in adolescents with tetralogy of Fallot. J Pediatr. 2015 Jan; 166(1):132-8. View Abstract
  290. Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease. Circulation. 2014 Sep 30; 130(14):1192-203. View Abstract
  291. Cardiology patient page. Neurodevelopmental outcomes in congenital heart disease. Circulation. 2014 Sep 30; 130(14):e124-6. View Abstract
  292. White matter microstructure and cognition in adolescents with congenital heart disease. J Pediatr. 2014 Nov; 165(5):936-44.e1-2. View Abstract
  293. Multivessel giant coronary artery aneurysms in an adult with an acute coronary syndrome: latent finding of Kawasaki disease. J Invasive Cardiol. 2014 Sep; 26(9):E127-9. View Abstract
  294. Validation of association of the apolipoprotein E e2 allele with neurodevelopmental dysfunction after cardiac surgery in neonates and infants. J Thorac Cardiovasc Surg. 2014 Dec; 148(6):2560-6. View Abstract
  295. Psychiatric disorders and function in adolescents with d-transposition of the great arteries. J Pediatr. 2014 Oct; 165(4):760-6. View Abstract
  296. Longitudinal assessment of growth in hypoplastic left heart syndrome: results from the single ventricle reconstruction trial. J Am Heart Assoc. 2014 Jun 23; 3(3):e000079. View Abstract
  297. Factors associated with neurodevelopment for children with single ventricle lesions. J Pediatr. 2014 Sep; 165(3):490-496.e8. View Abstract
  298. Technical performance score is associated with outcomes after the Norwood procedure. J Thorac Cardiovasc Surg. 2014 Nov; 148(5):2208-13, 2214.e1-6. View Abstract
  299. Impact of empiric nesiritide or milrinone infusion on early postoperative recovery after Fontan surgery: a randomized, double-blind, placebo-controlled trial. Circ Heart Fail. 2014 Jul; 7(4):596-604. View Abstract
  300. Cerebral blood flow velocity and neurodevelopmental outcome in infants undergoing surgery for congenital heart disease. Ann Thorac Surg. 2014 Jul; 98(1):125-32. View Abstract
  301. Temporal trends in pulse pressure and mean arterial pressure during the rise of pediatric obesity in US children. J Am Heart Assoc. 2014 May 08; 3(3):e000725. View Abstract
  302. Accelerated degeneration of a bovine pericardial bioprosthetic aortic valve in children and young adults. Circulation. 2014 Jul 01; 130(1):51-60. View Abstract
  303. Transplantation-free survival and interventions at 3 years in the single ventricle reconstruction trial. Circulation. 2014 May 20; 129(20):2013-20. View Abstract
  304. Myocardial extracellular remodeling is associated with ventricular diastolic dysfunction in children and young adults with congenital aortic stenosis. J Am Coll Cardiol. 2014 May 06; 63(17):1778-85. View Abstract
  305. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation. 2014 Mar 04; 129(9):1048-78. View Abstract
  306. Adolescents with tetralogy of Fallot: neuropsychological assessment and structural brain imaging. Cardiol Young. 2015 Feb; 25(2):338-47. View Abstract
  307. Health-related quality of life outcomes in children and adolescents with congenital heart disease. J Pediatr. 2014 Apr; 164(4):781-788.e1. View Abstract
  308. Hypoplastic left coronary artery with large collateral vessels from an ectatic right coronary artery: multimodality imaging-based diagnostic work-up. Int J Cardiol. 2014 Apr 01; 172(3):e396-7. View Abstract
  309. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2013 Dec 17; 128(24):2622-703. View Abstract
  310. Association between Technical Performance Scores and neurodevelopmental outcomes after congenital cardiac surgery. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):232-237.e3. View Abstract
  311. Effect of copy number variants on outcomes for infants with single ventricle heart defects. Circ Cardiovasc Genet. 2013 Oct; 6(5):444-51. View Abstract
  312. Coronary artery outcomes among children with Kawasaki disease in the United States and Japan. Int J Cardiol. 2013 Oct 09; 168(4):3825-8. View Abstract
  313. Vascular health in Kawasaki disease. J Am Coll Cardiol. 2013 Sep 17; 62(12):1114-1121. View Abstract
  314. Clopidogrel in infants with systemic-to-pulmonary-artery shunts. N Engl J Med. 2013 Jun 20; 368(25):2377-84. View Abstract
  315. The impact of socio-economic status on health related quality of life for children and adolescents with heart disease. Health Qual Life Outcomes. 2013 Jun 18; 11:99. View Abstract
  316. Functional health status in children and adolescents after Fontan: comparison of generic and disease-specific assessments. Cardiol Young. 2014 Jun; 24(3):469-77. View Abstract
  317. De novo mutations in histone-modifying genes in congenital heart disease. Nature. 2013 Jun 13; 498(7453):220-3. View Abstract
  318. Standardized Clinical Assessment And Management Plans (SCAMPs) provide a better alternative to clinical practice guidelines. Health Aff (Millwood). 2013 May; 32(5):911-20. View Abstract
  319. Kawasaki disease. Pediatr Rev. 2013 Apr; 34(4):151-62. View Abstract
  320. Design and rationale of safe pediatric euglycemia after cardiac surgery: a randomized controlled trial of tight glycemic control after pediatric cardiac surgery. Pediatr Crit Care Med. 2013 Feb; 14(2):148-56. View Abstract
  321. Adolescents with D-transposition of the great arteries repaired in early infancy demonstrate reduced white matter microstructure associated with clinical risk factors. J Thorac Cardiovasc Surg. 2013 Sep; 146(3):543-9.e1. View Abstract
  322. Coronary artery dimensions in febrile children without Kawasaki disease. Circ Cardiovasc Imaging. 2013 Mar 01; 6(2):239-44. View Abstract
  323. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease. EMBO Mol Med. 2013 Feb; 5(2):210-20. View Abstract
  324. Cardiovascular outcomes after the arterial switch operation for D-transposition of the great arteries. Circulation. 2013 Jan 22; 127(3):331-9. View Abstract
  325. Adding prednisolone to standard immunoglobulin therapy is beneficial for patients with severe Kawasaki disease. J Pediatr. 2012 Nov; 161(5):967. View Abstract
  326. Delayed cortical development in fetuses with complex congenital heart disease. Cereb Cortex. 2013 Dec; 23(12):2932-43. View Abstract
  327. Clinical outcome score predicts the need for neurodevelopmental intervention after infant heart surgery. J Thorac Cardiovasc Surg. 2013 May; 145(5):1248-1254.e2. View Abstract
  328. Association of impaired linear growth and worse neurodevelopmental outcome in infants with single ventricle physiology: a report from the pediatric heart network infant single ventricle trial. J Pediatr. 2013 Feb; 162(2):250-6.e2. View Abstract
  329. A predictive model for neurodevelopmental outcome after the Norwood procedure. Pediatr Cardiol. 2013 Feb; 34(2):327-33. View Abstract
  330. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. Circulation. 2012 Aug 28; 126(9):1143-72. View Abstract
  331. Quality of life of pediatric cardiac patients who previously required extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2012 Jul; 13(4):428-34. View Abstract
  332. Variation in perioperative care across centers for infants undergoing the Norwood procedure. J Thorac Cardiovasc Surg. 2012 Oct; 144(4):915-21. View Abstract
  333. Genetics insights into the pathogenesis of Kawasaki disease. Circ Cardiovasc Genet. 2012 Jun; 5(3):277-8. View Abstract
  334. Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. Circulation. 2012 May 29; 125(21):2621-9. View Abstract
  335. Trends in endocarditis hospitalizations at US children's hospitals: impact of the 2007 American Heart Association Antibiotic Prophylaxis Guidelines. Am Heart J. 2012 May; 163(5):894-9. View Abstract
  336. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation. 2012 May 22; 125(20):2520-44. View Abstract
  337. Early developmental outcome in children with hypoplastic left heart syndrome and related anomalies: the single ventricle reconstruction trial. Circulation. 2012 May 01; 125(17):2081-91. View Abstract
  338. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012 Mar 25; 44(5):517-21. View Abstract
  339. Management of Kawasaki disease: corticosteroids revisited. Lancet. 2012 Apr 28; 379(9826):1571-2. View Abstract
  340. Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis. Pediatrics. 2012 Apr; 129(4):e999-1010. View Abstract
  341. Neurodevelopmental outcomes after congenital heart surgery and strategies for improvement. Curr Opin Cardiol. 2012 Mar; 27(2):82-91. View Abstract
  342. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet. 2011 Nov 13; 43(12):1241-6. View Abstract
  343. Provider attitudes toward Standardized Clinical Assessment and Management Plans (SCAMPs). Congenit Heart Dis. 2011 Nov-Dec; 6(6):558-65. View Abstract
  344. Donald Charles Fyler: 1924–2011. Cardiol Young. 2011 Oct; 21(5):485-9. View Abstract
  345. Adolescents with d-transposition of the great arteries corrected with the arterial switch procedure: neuropsychological assessment and structural brain imaging. Circulation. 2011 Sep 20; 124(12):1361-9. View Abstract
  346. Practice variability and outcomes of coil embolization of aortopulmonary collaterals before Fontan completion: a report from the Pediatric Heart Network Fontan Cross-Sectional Study. Am Heart J. 2011 Jul; 162(1):125-30. View Abstract
  347. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. J Med Genet. 2011 Jul; 48(7):467-72. View Abstract
  348. Marketing code of ethics for pediatric cardiology programs. Congenit Heart Dis. 2011 May-Jun; 6(3):209-10. View Abstract
  349. Hemodynamic correlates of serum cortisol in neonates after cardiopulmonary bypass. Pediatr Crit Care Med. 2011 May; 12(3):297-303. View Abstract
  350. A summary of the update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. J Am Dent Assoc. 2011 Feb; 142(2):159-65. View Abstract
  351. Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study. Am Heart J. 2011 Feb; 161(2):233-40. View Abstract
  352. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol. 2011 Jan 04; 57(1):86-92. View Abstract
  353. Predictors of coronary artery visualization in Kawasaki disease. J Am Soc Echocardiogr. 2011 Jan; 24(1):53-9. View Abstract
  354. Congenital portosystemic venous connections and other abdominal venous abnormalities in patients with polysplenia and functionally univentricular heart disease: a case series and literature review. Congenit Heart Dis. 2011 Jan-Feb; 6(1):28-40. View Abstract
  355. Clinical research careers: reports from a NHLBI pediatric heart network clinical research skills development conference. Am Heart J. 2011 Jan; 161(1):13-67. View Abstract
  356. Blood transfusion is associated with prolonged duration of mechanical ventilation in infants undergoing reparative cardiac surgery. Pediatr Crit Care Med. 2011 Jan; 12(1):52-6. View Abstract
  357. Management and outcomes in pediatric patients presenting with acute fulminant myocarditis. J Pediatr. 2011 Apr; 158(4):638-643.e1. View Abstract
  358. External validity of the pediatric cardiac quality of life inventory. Qual Life Res. 2011 Mar; 20(2):205-14. View Abstract
  359. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011 May; 158(5):831-835.e3. View Abstract
  360. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011 Apr; 158(4):644-649.e1. View Abstract
  361. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet. 2011 Feb; 4(1):16-25. View Abstract
  362. Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. J Hum Genet. 2010 Dec; 55(12):779-84. View Abstract
  363. The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg. 2010 Nov; 111(5):1244-51. View Abstract
  364. Validation of the pediatric cardiac quality of life inventory. Pediatrics. 2010 Sep; 126(3):498-508. View Abstract
  365. Relationship of intraoperative cerebral oxygen saturation to neurodevelopmental outcome and brain magnetic resonance imaging at 1 year of age in infants undergoing biventricular repair. Circulation. 2010 Jul 20; 122(3):245-54. View Abstract
  366. Deciding without data. Congenit Heart Dis. 2010 Jul-Aug; 5(4):339-42. View Abstract
  367. A novel approach to gathering and acting on relevant clinical information: SCAMPs. Congenit Heart Dis. 2010 Jul-Aug; 5(4):343-53. View Abstract
  368. Resource utilization after introduction of a standardized clinical assessment and management plan. Congenit Heart Dis. 2010 Jul-Aug; 5(4):374-81. View Abstract
  369. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med. 2010 May 27; 362(21):1980-92. View Abstract
  370. Coronary revascularization in patients with Kawasaki disease. J Pediatr. 2010 Jul; 157(1):8-10. View Abstract
  371. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet. 2010 Jul 15; 19(14):2898-906. View Abstract
  372. Antiplatelet therapy in pediatric cardiovascular patients. Pediatr Cardiol. 2010 May; 31(4):454-61. View Abstract
  373. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics. 2010 Feb; 125(2):e234-41. View Abstract
  374. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010 Jan 26; 121(3):458-77. View Abstract
  375. Brain volume and metabolism in fetuses with congenital heart disease: evaluation with quantitative magnetic resonance imaging and spectroscopy. Circulation. 2010 Jan 05; 121(1):26-33. View Abstract
  376. Diastolic function in children with Kawasaki disease. Int J Cardiol. 2011 May 05; 148(3):309-12. View Abstract
  377. Parent- versus child-reported functional health status after the Fontan procedure. Pediatrics. 2009 Nov; 124(5):e942-9. View Abstract
  378. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the AHA and AAP. Pediatrics. 2009 Aug; 124(2):823-36. View Abstract
  379. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics. Circulation. 2009 Aug 04; 120(5):447-58. View Abstract
  380. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009 Jul; 124(1):1-8. View Abstract
  381. Functional state following the Fontan procedure. Cardiol Young. 2009 Aug; 19(4):320-30. View Abstract
  382. Subtle hemorrhagic brain injury is associated with neurodevelopmental impairment in infants with repaired congenital heart disease. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):374-81. View Abstract
  383. Cerebral oximetry during infant cardiac surgery: evaluation and relationship to early postoperative outcome. Anesth Analg. 2009 Apr; 108(4):1122-31. View Abstract
  384. Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. J Pediatr. 2009 Jun; 154(6):901-5. View Abstract
  385. Characteristics of children hospitalized with infective endocarditis. Circulation. 2009 Feb 17; 119(6):865-70. View Abstract
  386. Behaviour at eight years in children with surgically corrected transposition: The Boston Circulatory Arrest Trial. Cardiol Young. 2009 Feb; 19(1):86-97. View Abstract
  387. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr. 2009 Apr; 154(4):592-595.e2. View Abstract
  388. Reexamining the emperor's new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder. Circ Cardiovasc Qual Outcomes. 2008 Nov; 1(2):134-7. View Abstract
  389. Cardiology patient pages. Kawasaki disease. Circulation. 2008 Aug 12; 118(7):e110-2. View Abstract
  390. Facial nerve palsy complicating Kawasaki disease. Pediatrics. 2008 Sep; 122(3):e783-5. View Abstract
  391. Design and rationale of a randomized trial comparing the Blalock-Taussig and right ventricle-pulmonary artery shunts in the Norwood procedure. J Thorac Cardiovasc Surg. 2008 Oct; 136(4):968-75. View Abstract
  392. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008 Jul; 153(1):117-21. View Abstract
  393. Randomized trial of hematocrit 25% versus 35% during hypothermic cardiopulmonary bypass in infant heart surgery. J Thorac Cardiovasc Surg. 2008 Feb; 135(2):347-54, 354.e1-4. View Abstract
  394. The effect of hematocrit during hypothermic cardiopulmonary bypass in infant heart surgery: results from the combined Boston hematocrit trials. J Thorac Cardiovasc Surg. 2008 Feb; 135(2):355-60. View Abstract
  395. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc. 2008 Jan; 139 Suppl:3S-24S. View Abstract
  396. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008 Jan; 40(1):35-42. View Abstract
  397. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics. 2007 Dec; 120(6):e1434-40. View Abstract
  398. Postoperative hypothermia and blood loss after the neonatal arterial switch procedure. Ann Thorac Surg. 2007 Nov; 84(5):1627-32. View Abstract
  399. Are patients with Kawasaki disease at risk for premature atherosclerosis? J Pediatr. 2007 Sep; 151(3):225-8. View Abstract
  400. Characteristics of children discharged from hospitals in the United States in 2000 with the diagnosis of acute rheumatic fever. Pediatrics. 2007 Sep; 120(3):503-8. View Abstract
  401. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation. 2007 Jul 10; 116(2):174-9. View Abstract
  402. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc. 2007 Jun; 138(6):739-45, 747-60. View Abstract
  403. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. J Cardiovasc Nurs. 2007 May-Jun; 22(3):218-53. View Abstract
  404. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct 09; 116(15):1736-54. View Abstract
  405. Kawasaki disease. Curr Treat Options Cardiovasc Med. 2007 Apr; 9(2):148-58. View Abstract
  406. Cerebral perfusion and oxygenation after the Norwood procedure: comparison of right ventricle-pulmonary artery conduit with modified Blalock-Taussig shunt. J Thorac Cardiovasc Surg. 2007 Mar; 133(3):648-55. View Abstract
  407. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007 Feb 15; 356(7):663-75. View Abstract
  408. Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol. 2007; 8(12):R261. View Abstract
  409. Cardiac troponin increases among runners in the Boston Marathon. Ann Emerg Med. 2007 Feb; 49(2):137-43, 143.e1. View Abstract
  410. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006 Dec 12; 114(24):2710-38. View Abstract
  411. Factors determining access to surgery for children with congenital cardiac disease in Guatemala, Central America. Cardiol Young. 2006 Aug; 16(4):385-91. View Abstract
  412. Inflammation and changes in metabolic syndrome abnormalities in US adolescents: findings from the 1988-1994 and 1999-2000 National Health and Nutrition Examination Surveys. Clin Chem. 2006 Jul; 52(7):1325-30. View Abstract
  413. Early postoperative outcomes in a series of infants with hypoplastic left heart syndrome undergoing stage I palliation operation with either modified Blalock-Taussig shunt or right ventricle to pulmonary artery conduit. Pediatr Crit Care Med. 2006 May; 7(3):238-44. View Abstract
  414. The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease. Pediatr Cardiol. 2006 Mar-Apr; 27(2):191-8. View Abstract
  415. Relationship of patient and medical characteristics to health status in children and adolescents after the Fontan procedure. Circulation. 2006 Feb 28; 113(8):1123-9. View Abstract
  416. Brain injury in congenital heart disease. Circulation. 2006 Jan 17; 113(2):183-5. View Abstract
  417. An evaluation of bilateral monitoring of cerebral oxygen saturation during pediatric cardiac surgery. Anesth Analg. 2005 Nov; 101(5):1294-1300. View Abstract
  418. Hypoxic-ischemic brain injury in infants with congenital heart disease dying after cardiac surgery. Acta Neuropathol. 2005 Dec; 110(6):563-78. View Abstract
  419. Familial occurrence of Kawasaki syndrome in North America. Arch Pediatr Adolesc Med. 2005 Sep; 159(9):876-81. View Abstract
  420. A randomized, double-blind, placebo-controlled pilot trial of triiodothyronine in neonatal heart surgery. J Thorac Cardiovasc Surg. 2005 Sep; 130(3):810-6. View Abstract
  421. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun. 2005 Aug; 6(5):438-44. View Abstract
  422. Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases. Clin Exp Immunol. 2005 Jul; 141(1):183-8. View Abstract
  423. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005 Jun 14; 111(23):e394-434. View Abstract
  424. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis. 2005 Jul 15; 192(2):344-9. View Abstract
  425. Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics. 2005 Jul; 116(1):e89-93. View Abstract
  426. Task Force 2: congenital heart disease. J Am Coll Cardiol. 2005 Apr 19; 45(8):1326-33. View Abstract
  427. Hyponatremia among runners in the Boston Marathon. N Engl J Med. 2005 Apr 14; 352(15):1550-6. View Abstract
  428. Focal seizure and cerebral contrast retention after cardiac catheterization. Pediatr Neurol. 2005 Mar; 32(3):213-6. View Abstract
  429. Risk factors for readmission after neonatal cardiac surgery. Ann Thorac Surg. 2004 Dec; 78(6):1972-8; discussion 1978. View Abstract
  430. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004 Dec; 114(6):1708-33. View Abstract
  431. Identification of pressure passive cerebral perfusion and its mediators after infant cardiac surgery. Pediatr Res. 2005 Jan; 57(1):35-41. View Abstract
  432. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004 Oct 26; 110(17):2747-71. View Abstract
  433. Prediction of IQ and achievement at age 8 years from neurodevelopmental status at age 1 year in children with D-transposition of the great arteries. Pediatrics. 2004 Nov; 114(5):e572-6. View Abstract
  434. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation. 2004 Oct 19; 110(16):2494-7. View Abstract
  435. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest. 2004 Oct; 126(4):1255-61. View Abstract
  436. Kawasaki disease. Curr Opin Pediatr. 2004 Oct; 16(5):508-14. View Abstract
  437. Recombinant human growth hormone treatment for dilated cardiomyopathy in children. Pediatrics. 2004 Oct; 114(4):e452-8. View Abstract
  438. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004 Sep; 145(3):353-9. View Abstract
  439. Intraoperative hyperglycemia during infant cardiac surgery is not associated with adverse neurodevelopmental outcomes at 1, 4, and 8 years. Anesthesiology. 2004 Jun; 100(6):1345-52. View Abstract
  440. Effect of prenatal diagnosis on outcomes in D-transposition of the great arteries. Pediatrics. 2004 Apr; 113(4):e335-40. View Abstract
  441. Nonvalvular cardiovascular device-related infections. Clin Infect Dis. 2004 Apr 15; 38(8):1128-30. View Abstract
  442. Alexander Sandor Nadas: November 12, 1913 - May 15, 2000. Cardiol Young. 2004 Feb; 14(1):75-82. View Abstract
  443. Early postoperative body temperature and developmental outcome after open heart surgery in infants. Ann Thorac Surg. 2004 Jan; 77(1):66-71; discussion 71. View Abstract
  444. The influence of hemodilution on outcome after hypothermic cardiopulmonary bypass: results of a randomized trial in infants. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1765-74. View Abstract
  445. Neurodevelopmental status at eight years in children with dextro-transposition of the great arteries: the Boston Circulatory Arrest Trial. J Thorac Cardiovasc Surg. 2003 Nov; 126(5):1385-96. View Abstract
  446. The effect of duration of deep hypothermic circulatory arrest in infant heart surgery on late neurodevelopment: the Boston Circulatory Arrest Trial. J Thorac Cardiovasc Surg. 2003 Nov; 126(5):1397-403. View Abstract
  447. Nonvalvular cardiovascular device-related infections. Circulation. 2003 Oct 21; 108(16):2015-31. View Abstract
  448. Length of stay after infant heart surgery is related to cognitive outcome at age 8 years. J Pediatr. 2003 Jul; 143(1):67-73. View Abstract
  449. Visual-spatial skills in children after open-heart surgery. J Dev Behav Pediatr. 2003 Jun; 24(3):169-79. View Abstract
  450. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003 Jun; 142(6):611-6. View Abstract
  451. Physical and psychosocial health in children who have had Kawasaki disease. Pediatrics. 2003 Mar; 111(3):579-83. View Abstract
  452. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003 Mar 01; 91(5):632-5. View Abstract
  453. Time course of early induction of intracellular adhesion molecule-1 messenger RNA during reperfusion, following cardiopulmonary bypass with hypothermic circulatory arrest in lambs. Pediatr Crit Care Med. 2003 Jan; 4(1):83-8. View Abstract
  454. Ethical issues concerning cardiac surgery in patients with syndromic abnormalities. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2003; 6:147-51. View Abstract
  455. Summary and abstracts of the Seventh International Kawasaki Disease Symposium: December 4-7, 2001, Hakone, Japan. Pediatr Res. 2003 Jan; 53(1):153-7. View Abstract
  456. Neurologic and developmental morbidity in children with complex congenital heart disease. J Pediatr. 2003 Jan; 142(1):6-8. View Abstract
  457. Influence of parental stress and social support on the behavioral adjustment of children with transposition of the great arteries. J Dev Behav Pediatr. 2002 Oct; 23(5):314-21. View Abstract
  458. Neurologic outcome of choreoathetoid encephalopathy after cardiac surgery. Pediatr Neurol. 2002 Jul; 27(1):9-17. View Abstract
  459. Current incidence of acute neurologic complications after open-heart operations in children. Ann Thorac Surg. 2002 Jun; 73(6):1752-8. View Abstract
  460. Unique features of infective endocarditis in childhood. Pediatrics. 2002 May; 109(5):931-43. View Abstract
  461. Unique features of infective endocarditis in childhood. Circulation. 2002 Apr 30; 105(17):2115-26. View Abstract
  462. Coronary magnetic resonance angiography in adolescents and young adults with kawasaki disease. Circulation. 2002 Feb 26; 105(8):908-11. View Abstract
  463. Consensus-based method for risk adjustment for surgery for congenital heart disease. J Thorac Cardiovasc Surg. 2002 Jan; 123(1):110-8. View Abstract
  464. Myocardial immediate early gene activation after cardiopulmonary bypass with cardiac ischemia-reperfusion. Ann Thorac Surg. 2002 Jan; 73(1):156-62. View Abstract
  465. General health status of children with D-transposition of the great arteries after the arterial switch operation. Circulation. 2001 Sep 18; 104(12 Suppl 1):I138-42. View Abstract
  466. Hyperlipidemia in children and adolescents. Am Heart J. 2001 Sep; 142(3):433-9. View Abstract
  467. Ethical issues in pediatric trials. Am Heart J. 2001 Aug; 142(2):233-6. View Abstract
  468. Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease. Pediatr Res. 2001 May; 49(5):686-90. View Abstract
  469. Work-family issues and perceptions of stress among pediatric faculty and house staff. Ambul Pediatr. 2001 May-Jun; 1(3):141-9. View Abstract
  470. Aortic root dilation in Kawasaki disease. Am J Cardiol. 2001 Apr 01; 87(7):919-22. View Abstract
  471. Developmental and neurologic effects of alpha-stat versus pH-stat strategies for deep hypothermic cardiopulmonary bypass in infants. J Thorac Cardiovasc Surg. 2001 Feb; 121(2):374-83. View Abstract
  472. Exogenous growth hormone: a new therapy for dilated cardiomyopathy. Prog Pediatr Cardiol. 2000 Nov 04; 12(1):125-132. View Abstract
  473. Psoriatic eruption in Kawasaki disease. J Pediatr. 2000 Oct; 137(4):578-80. View Abstract
  474. Cognitive development after the Fontan operation. Circulation. 2000 Aug 22; 102(8):883-9. View Abstract
  475. Kawasaki disease: who is at risk? J Pediatr. 2000 Aug; 137(2):149-52. View Abstract
  476. Long-term cardiac sequelae of Kawasaki disease. Curr Rheumatol Rep. 2000 Aug; 2(4):324-9. View Abstract
  477. The impact of managed care insurance on use of lower-mortality hospitals by children undergoing cardiac surgery in California. Pediatrics. 2000 Jun; 105(6):1271-8. View Abstract
  478. Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. Pediatrics. 2000 May; 105(5):E64. View Abstract
  479. The relationship between managed care insurance and use of lower-mortality hospitals for CABG surgery. JAMA. 2000 Apr 19; 283(15):1976-82. View Abstract
  480. Abnormal myocardial mechanics in Kawasaki disease: rapid response to gamma-globulin. Am Heart J. 2000 Feb; 139(2 Pt 1):217-23. View Abstract
  481. Developmental outcome after surgical versus interventional closure of secundum atrial septal defect in children. Circulation. 1999 Nov 09; 100(19 Suppl):II145-50. View Abstract
  482. Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr. 1999 Oct; 135(4):411-3. View Abstract
  483. Developmental and neurological status of children at 4 years of age after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. Circulation. 1999 Aug 03; 100(5):526-32. View Abstract
  484. The effect of hematocrit on cerebral blood flow velocity in neonates and infants undergoing deep hypothermic cardiopulmonary bypass. Anesth Analg. 1999 Aug; 89(2):322-7. View Abstract
  485. Comparison of outcome when hypoplastic left heart syndrome and transposition of the great arteries are diagnosed prenatally versus when diagnosis of these two conditions is made only postnatally. Am J Cardiol. 1999 Jun 15; 83(12):1649-53. View Abstract
  486. Kawasaki disease. Vasc Med. 1999; 4(3):187-202. View Abstract
  487. Diagnosis and management of infective endocarditis and its complications. Circulation. 1998 Dec 22-29; 98(25):2936-48. View Abstract
  488. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998 Dec; 17(12):1144-8. View Abstract
  489. Validation of relative value scale for congenital heart operations. Ann Thorac Surg. 1998 Sep; 66(3):860-9. View Abstract
  490. Utility of direct measurement of low-density lipoprotein cholesterol in dyslipidemic pediatric patients. Arch Pediatr Adolesc Med. 1998 Aug; 152(8):787-91. View Abstract
  491. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr. 1998 Aug; 133(2):254-8. View Abstract
  492. Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J. 1998 Jun; 17(6):478-81. View Abstract
  493. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol. 1998 May 01; 81(9):1116-20. View Abstract
  494. Relation of seizures after cardiac surgery in early infancy to neurodevelopmental outcome. Boston Circulatory Arrest Study Group. Circulation. 1998 Mar 03; 97(8):773-9. View Abstract
  495. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin Infect Dis. 1997 Dec; 25(6):1448-58. View Abstract
  496. Perioperative effects of alpha-stat versus pH-stat strategies for deep hypothermic cardiopulmonary bypass in infants. J Thorac Cardiovasc Surg. 1997 Dec; 114(6):991-1000; discussion 1000-1. View Abstract
  497. Soluble adhesion molecules in infants and children undergoing cardiopulmonary bypass. Circulation. 1997 Nov 04; 96(9 Suppl):II-352-7. View Abstract
  498. Passive cigarette smoking and reduced HDL cholesterol levels in children with high-risk lipid profiles. Circulation. 1997 Sep 02; 96(5):1403-7. View Abstract
  499. Fontan operation in five hundred consecutive patients: factors influencing early and late outcome. J Thorac Cardiovasc Surg. 1997 Sep; 114(3):376-91. View Abstract
  500. Functional outcome after the Fontan operation: factors influencing late morbidity. J Thorac Cardiovasc Surg. 1997 Sep; 114(3):392-403; discussion 404-5. View Abstract
  501. Prevention of bacterial endocarditis: recommendations by the American Heart Association. J Am Dent Assoc. 1997 Aug; 128(8):1142-51. View Abstract
  502. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation. 1997 Jul 01; 96(1):358-66. View Abstract
  503. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA. 1997 Jun 11; 277(22):1794-801. View Abstract
  504. Patterns of developmental dysfunction after surgery during infancy to correct transposition of the great arteries. J Dev Behav Pediatr. 1997 Apr; 18(2):75-83. View Abstract
  505. Perioperative electroencephalographic seizures in infants undergoing repair of complex congenital cardiac defects. Electroencephalogr Clin Neurophysiol. 1997 Jan; 102(1):27-36. View Abstract
  506. Viral myocarditis: diagnosis and management. Adv Pediatr. 1997; 44:141-71. View Abstract
  507. Analytical performance and clinical utility of a direct LDL-cholesterol assay in a hyperlipidemic pediatric population. Clin Chem. 1996 Aug; 42(8 Pt 1):1182-8. View Abstract
  508. Treatment of Kawasaki disease. Lancet. 1996 Apr 27; 347(9009):1128. View Abstract
  509. Cerebral oxygenation during hypothermic cardiopulmonary bypass: clinical findings support mathematical model. Anesthesiology. 1996 Apr; 84(4):1008-9. View Abstract
  510. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996 Jan; 128(1):146-9. View Abstract
  511. Induction of interleukin-8 messenger RNA in heart and skeletal muscle during pediatric cardiopulmonary bypass. Circulation. 1995 Nov 01; 92(9 Suppl):II315-21. View Abstract
  512. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation. 1995 Oct 15; 92(8):2226-35. View Abstract
  513. P-selectin expression in myocardium of children undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1995 Oct; 110(4 Pt 1):924-33. View Abstract
  514. Conjunctival biopsy in patients with Kawasaki disease. Pediatr Pathol Lab Med. 1995 Jul-Aug; 15(4):547-53. View Abstract
  515. Cerebral oxygen supply and utilization during infant cardiac surgery. Ann Neurol. 1995 Apr; 37(4):488-97. View Abstract
  516. Cerebrovascular accidents following the Fontan operation. Pediatr Neurol. 1995 Apr; 12(3):230-6. View Abstract
  517. In-hospital mortality for surgical repair of congenital heart defects: preliminary observations of variation by hospital caseload. Pediatrics. 1995 Mar; 95(3):323-30. View Abstract
  518. Induction of intercellular adhesion molecule-1 and E-selectin mRNA in heart and skeletal muscle of pediatric patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994 May; 107(5):1183-92. View Abstract
  519. Seroprevalence of human herpesvirus 7 in patients with Kawasaki disease. Pediatr Infect Dis J. 1994 Feb; 13(2):168-9. View Abstract
  520. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994 Jan; 89(1):252-7. View Abstract
  521. Kawasaki disease and its cardiac sequelae. Hosp Pract (Off Ed). 1993 Nov 15; 28(11):51-4, 57-60, 64-6. View Abstract
  522. A comparison of the perioperative neurologic effects of hypothermic circulatory arrest versus low-flow cardiopulmonary bypass in infant heart surgery. N Engl J Med. 1993 Oct 07; 329(15):1057-64. View Abstract
  523. Gamma globulin re-treatment in Kawasaki disease. J Pediatr. 1993 Oct; 123(4):657-9. View Abstract
  524. Relation of pH strategy and developmental outcome after hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 1993 Aug; 106(2):362-8. View Abstract
  525. Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993 Jul; 92(1):78-82. View Abstract
  526. Effects of nutritional counseling on lipoprotein levels in a pediatric lipid clinic. Am J Dis Child. 1993 Apr; 147(4):378-81. View Abstract
  527. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992 Dec; 86(6):1902-8. View Abstract
  528. Audiologic profiles of children with Kawasaki disease. Am J Otol. 1992 Nov; 13(6):512-5. View Abstract
  529. Quantitation of lysophosphatidylcholine molecular species in rat cardiac tissue. Anal Biochem. 1992 Jul; 204(1):72-8. View Abstract
  530. A survey of pediatric management of dyslipidemias in New England. Pediatr Cardiol. 1992 Apr; 13(2):76-9. View Abstract
  531. Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. J Pediatr. 1992 Mar; 120(3):376-80. View Abstract
  532. The HLA class II region and susceptibility to Kawasaki disease. Tissue Antigens. 1992 Feb; 39(2):99-101. View Abstract
  533. Spectrum of renal anomalies in patients with Williams syndrome. J Pediatr. 1991 Nov; 119(5):771-3. View Abstract
  534. Altered lipid profile after Kawasaki syndrome. Circulation. 1991 Aug; 84(2):625-31. View Abstract
  535. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991 Jun 06; 324(23):1633-9. View Abstract
  536. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr. 1991 May; 118(5):680-6. View Abstract
  537. Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides. J Pharmacol Exp Ther. 1991 Apr; 257(1):156-62. View Abstract
  538. Decreased protein binding of salicylates in Kawasaki disease. J Pediatr. 1991 Mar; 118(3):456-9. View Abstract
  539. Cognitive development of children following early repair of transposition of the great arteries using deep hypothermic circulatory arrest. Pediatrics. 1991; 87:701-7. View Abstract
  540. Sensorineural hearing loss associated with Kawasaki disease. J Pediatr. 1990 Sep; 117(3):371-7. View Abstract
  541. Characterization of the polymerase activity associated with cultured peripheral blood mononuclear cells from patients with Kawasaki disease. Pediatr Res. 1990 Feb; 27(2):109-12. View Abstract
  542. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet. 1989 Dec 02; 2(8675):1298-302. View Abstract
  543. Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin. Circulation. 1989 Jun; 79(6):1237-46. View Abstract
  544. Kawasaki syndrome. Cardiol Clin. 1989 May; 7(2):453-65. View Abstract
  545. Kawasaki disease and cervical adenopathy. Arch Otolaryngol Head Neck Surg. 1989 Apr; 115(4):512-4. View Abstract
  546. Kawasaki syndrome and the eye. Pediatr Infect Dis J. 1989 Feb; 8(2):116-8. View Abstract
  547. Endothelial activation in the pathogenesis of Kawasaki disease. Trans Assoc Am Physicians. 1989; 102:131-8. View Abstract
  548. Kawasaki disease and cervical adenopathy: an update for the otolaryngologist. Arch Otolaryngol Head Neck Surg. 1989; 115:512-14. View Abstract
  549. Kawasaki's syndrome and the eye. Pediatr Inf Dis J. 1989; 8:116-18. View Abstract
  550. Increased prevalence of atopic dermatitis in Kawasaki disease. Pediatr Infect Dis J. 1988 Dec; 7(12):863-6. View Abstract
  551. Estimation of the rate constants in a data-sparse environment: comparison of a mathematical method and least squares analysis. J Pharm Sci. 1988 Feb; 77(2):175-7. View Abstract
  552. Human pharmacokinetics of ethynyl estradiol 3-sulfate and 17-sulfate. Steroids. 1988 Jan-Feb; 51(1-2):63-79. View Abstract
  553. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest. 1987 Feb; 79(2):468-72. View Abstract
  554. Polymerase activity in lymphocyte culture supernatants from patients with Kawasaki disease. Prog Clin Biol Res. 1987; 250:125-30. View Abstract
  555. U.S. gamma globulin trial. Prog Clin Biol Res. 1987; 250:441-3. View Abstract
  556. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med. 1986 Dec 01; 164(6):1958-72. View Abstract
  557. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr. 1986 Nov; 109(5):759-63. View Abstract
  558. Polymerase activity in lymphocyte culture supernatants from patients with Kawasaki disease. Nature. 1986 Oct 30-Nov 5; 323(6091):814-6. View Abstract
  559. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986 Aug 07; 315(6):341-7. View Abstract
  560. Pulmonary arterial changes in patients with ventricular septal defects and severe pulmonary hypertension. Pediatr Cardiol. 1986; 7(3):147-54. View Abstract
  561. The clinical spectrum of Kawasaki syndrome in infants less than six months of age. J Pediatr. 1986; 109:759-63. View Abstract
  562. Pharmacokinetics of ethynyl estradiol: a current view. Contraception. 1985 Jul; 32(1):33-44. View Abstract
  563. Cognitive function and age at repair of transposition of the great arteries in children. N Engl J Med. 1984 Jun 07; 310(23):1495-9. View Abstract
  564. Membrane solubility parameter and in situ release of theophylline. J Pharm Sci. 1984 Jun; 73(6):742-5. View Abstract
  565. Evaluation of the bioavailability of sarpicillin, the methoxymethyl ester of hetacillin, in humans. J Pharm Sci. 1984 Feb; 73(2):169-73. View Abstract
  566. The pharmacokinetics and metabolism of ethinyl estradiol and its three sulfates in the baboon. Am J Obstet Gynecol. 1983 May 01; 146(1):80-7. View Abstract
  567. Noninvasive tests in the initial evaluation of heart murmurs in children. N Engl J Med. 1983 Jan 13; 308(2):61-4. View Abstract
  568. Cyclosporin A tissue levels in a cadaveric renal allograft recipient. Transplantation. 1983 Jan; 35(1):96-9. View Abstract
  569. Blood pressure and haemodynamics in teenagers. Br Heart J. 1982 Oct; 48(4):377-80. View Abstract
  570. Marital stability and congenital heart disease. Pediatrics. 1982 Jun; 69(6):747-50. View Abstract
  571. Noninvasive estimation of central aortic pressure using the oscillometric method for analyzing systemic artery pulsatile blood flow: comparative study of indirect systolic, diastolic, and mean brachial artery pressure with simultaneous direct ascending aortic pressure measurements. Am Heart J. 1982 May; 103(5):879-86. View Abstract
  572. Pediatric aspects of essential hypertension. J Am Diet Assoc. 1982 Jan; 80(1):21-5. View Abstract
  573. A simplified method to estimate total area under the blood plasma concentration-versus-time curve. J Clin Pharmacol. 1980 Nov-Dec; 20(11):659-63. View Abstract
  574. Effect of time errors on infinity values obtained using Prony's method. J Pharm Sci. 1980 Oct; 69(10):1231-2. View Abstract
  575. Effect of time errors on infinity values obtained using Prony's method. J Pharm Sci. 1980 Oct; 69(10):1331-2. View Abstract
  576. Extended Hildebrand approach: solubility of caffeine in dioxane-water mixtures. J Pharm Sci. 1980 Jun; 69(6):659-61. View Abstract
  577. Extended Hildebrand solubility approach: solubility of theophylline in polar binary solvents. J Pharm Sci. 1980 May; 69(5):487-91. View Abstract
  578. A determinant solution for infinity values of multi-exponential equations using equal time intervals. Biopharm Drug Dispos. 1980 Jan-Mar; 1(3):119-22. View Abstract
  579. Iliac vein-inferior caval thrombosis after cardiac catheterization in infancy. Ped Cardiol. 1980; 1:257-61. View Abstract
  580. Intrauterine supraventricular tachycardia. J Pediatr. 1979 Nov; 95(5 Pt 1):780-6. View Abstract
  581. New solubility equation. J Pharm Sci. 1979 Oct; 68(10):IV-V. View Abstract
  582. A method to predict infinity values for biexponential processes. J Pharmacokinet Biopharm. 1979 Aug; 7(4):417-25. View Abstract
  583. High steady-state levels of uric acid produced in rats by dietary training and potassium oxonate. J Pharm Sci. 1979 May; 68(5):651-2. View Abstract
  584. Intrauterine supraventricular tachycardia; Clinical course, therapy and prognosis. J Pediatr. 1979; 95:780-786. View Abstract
  585. Diurnal variation in serum uric acid of rats fed potassium oxonate. Drug Chem Toxicol. 1978; 1(3):231-5. View Abstract
  586. In vitro photodecomposition of uric acid in presence of riboflavin II. J Pharm Sci. 1977 Nov; 66(11):1561-4. View Abstract
  587. A digital simulation program for health science students to follow drug levels in the body. Am J Pharm Educ. 1977 Aug; 41(3):275-8. View Abstract
  588. The effect of ion pair formation on the antimuscarinic activity of methantheline. Experientia. 1977 Jul 15; 33(7):936-8. View Abstract
  589. The effect of ion-pair formation on the lethal dose of methantheline bromide. Life Sci. 1977 Feb 15; 20(4):627-30. View Abstract
  590. In vitro photodecomposition of uric acid in the presence of riboflavin. Life Sci. 1975 Aug 01; 17(3):443-7. View Abstract

Contact Jane Newburger

Print Profile